Early clearance of circulating hepatitis C virus enhanced by induction therapy with twice-a-day intravenous injection of IFN-β

Fusao Ikeda, H. Shimomura, M. Miyake, S. I. Fujioka, M. Itoh, A. Takahashi, Yoshiaki Iwasaki, K. Sakaguchi, K. Yamamoto, T. Higashi, T. Tsuji

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

To improve the long-term efficacy of interferon (IFN) for treatment of chronic hepatitis C virus (HCV) infection, we proposed induction therapy with twice-a-day IFN-β injection. This study was intended to clarify the antiviral mechanism. Thirty patients were randomly assigned to two groups: group A (twice-a-day therapy) received 3 MU IFN-β intravenously (i.v.) twice a day for 2 weeks; group B (once-a-day therapy) received 6 MU of IFN-β daily. HCV RNA, IFN-β, alanine aminotransferase (ALT), 2'5'-oligoadenylate synthetase (2'5'-AS) activity, and β2-microglobulin in serum were compared between the two groups during the first 2 weeks of IFN therapy. The clearance rate of serum HCV RNA in group A (86.7%) was significantly higher than that in group B (13.3 %) at day 3 (p = 0.0006). No accumulation of IFN-β was shown in serum throughout the therapy. The ratio (day 3/day 1) of 2'5'-AS activity was significantly higher in group A. Multivariate analysis indicated twice-a-day IFN-β injection therapy led to significantly early clearance of circulating HCV. Twice-a-day IFN-β injection therapy could induce biologically enhanced antiviral activities and be an efficient induction therapy for eradication of HCV.

Original languageEnglish
Pages (from-to)831-836
Number of pages6
JournalJournal of Interferon and Cytokine Research
Volume20
Issue number9
DOIs
Publication statusPublished - 2000

Fingerprint

Virus Activation
Intravenous Injections
Hepacivirus
Interferons
Therapeutics
Ligases
Injections
Antiviral Agents
Serum
RNA
Chronic Hepatitis C
Virus Diseases
Alanine Transaminase
Multivariate Analysis

ASJC Scopus subject areas

  • Immunology
  • Virology
  • Cell Biology

Cite this

Early clearance of circulating hepatitis C virus enhanced by induction therapy with twice-a-day intravenous injection of IFN-β. / Ikeda, Fusao; Shimomura, H.; Miyake, M.; Fujioka, S. I.; Itoh, M.; Takahashi, A.; Iwasaki, Yoshiaki; Sakaguchi, K.; Yamamoto, K.; Higashi, T.; Tsuji, T.

In: Journal of Interferon and Cytokine Research, Vol. 20, No. 9, 2000, p. 831-836.

Research output: Contribution to journalArticle

Ikeda, Fusao ; Shimomura, H. ; Miyake, M. ; Fujioka, S. I. ; Itoh, M. ; Takahashi, A. ; Iwasaki, Yoshiaki ; Sakaguchi, K. ; Yamamoto, K. ; Higashi, T. ; Tsuji, T. / Early clearance of circulating hepatitis C virus enhanced by induction therapy with twice-a-day intravenous injection of IFN-β. In: Journal of Interferon and Cytokine Research. 2000 ; Vol. 20, No. 9. pp. 831-836.
@article{09e9bea83eaa4f91b780139ddc8217ff,
title = "Early clearance of circulating hepatitis C virus enhanced by induction therapy with twice-a-day intravenous injection of IFN-β",
abstract = "To improve the long-term efficacy of interferon (IFN) for treatment of chronic hepatitis C virus (HCV) infection, we proposed induction therapy with twice-a-day IFN-β injection. This study was intended to clarify the antiviral mechanism. Thirty patients were randomly assigned to two groups: group A (twice-a-day therapy) received 3 MU IFN-β intravenously (i.v.) twice a day for 2 weeks; group B (once-a-day therapy) received 6 MU of IFN-β daily. HCV RNA, IFN-β, alanine aminotransferase (ALT), 2'5'-oligoadenylate synthetase (2'5'-AS) activity, and β2-microglobulin in serum were compared between the two groups during the first 2 weeks of IFN therapy. The clearance rate of serum HCV RNA in group A (86.7{\%}) was significantly higher than that in group B (13.3 {\%}) at day 3 (p = 0.0006). No accumulation of IFN-β was shown in serum throughout the therapy. The ratio (day 3/day 1) of 2'5'-AS activity was significantly higher in group A. Multivariate analysis indicated twice-a-day IFN-β injection therapy led to significantly early clearance of circulating HCV. Twice-a-day IFN-β injection therapy could induce biologically enhanced antiviral activities and be an efficient induction therapy for eradication of HCV.",
author = "Fusao Ikeda and H. Shimomura and M. Miyake and Fujioka, {S. I.} and M. Itoh and A. Takahashi and Yoshiaki Iwasaki and K. Sakaguchi and K. Yamamoto and T. Higashi and T. Tsuji",
year = "2000",
doi = "10.1089/10799900050151102",
language = "English",
volume = "20",
pages = "831--836",
journal = "Journal of Interferon and Cytokine Research",
issn = "1079-9907",
publisher = "Mary Ann Liebert Inc.",
number = "9",

}

TY - JOUR

T1 - Early clearance of circulating hepatitis C virus enhanced by induction therapy with twice-a-day intravenous injection of IFN-β

AU - Ikeda, Fusao

AU - Shimomura, H.

AU - Miyake, M.

AU - Fujioka, S. I.

AU - Itoh, M.

AU - Takahashi, A.

AU - Iwasaki, Yoshiaki

AU - Sakaguchi, K.

AU - Yamamoto, K.

AU - Higashi, T.

AU - Tsuji, T.

PY - 2000

Y1 - 2000

N2 - To improve the long-term efficacy of interferon (IFN) for treatment of chronic hepatitis C virus (HCV) infection, we proposed induction therapy with twice-a-day IFN-β injection. This study was intended to clarify the antiviral mechanism. Thirty patients were randomly assigned to two groups: group A (twice-a-day therapy) received 3 MU IFN-β intravenously (i.v.) twice a day for 2 weeks; group B (once-a-day therapy) received 6 MU of IFN-β daily. HCV RNA, IFN-β, alanine aminotransferase (ALT), 2'5'-oligoadenylate synthetase (2'5'-AS) activity, and β2-microglobulin in serum were compared between the two groups during the first 2 weeks of IFN therapy. The clearance rate of serum HCV RNA in group A (86.7%) was significantly higher than that in group B (13.3 %) at day 3 (p = 0.0006). No accumulation of IFN-β was shown in serum throughout the therapy. The ratio (day 3/day 1) of 2'5'-AS activity was significantly higher in group A. Multivariate analysis indicated twice-a-day IFN-β injection therapy led to significantly early clearance of circulating HCV. Twice-a-day IFN-β injection therapy could induce biologically enhanced antiviral activities and be an efficient induction therapy for eradication of HCV.

AB - To improve the long-term efficacy of interferon (IFN) for treatment of chronic hepatitis C virus (HCV) infection, we proposed induction therapy with twice-a-day IFN-β injection. This study was intended to clarify the antiviral mechanism. Thirty patients were randomly assigned to two groups: group A (twice-a-day therapy) received 3 MU IFN-β intravenously (i.v.) twice a day for 2 weeks; group B (once-a-day therapy) received 6 MU of IFN-β daily. HCV RNA, IFN-β, alanine aminotransferase (ALT), 2'5'-oligoadenylate synthetase (2'5'-AS) activity, and β2-microglobulin in serum were compared between the two groups during the first 2 weeks of IFN therapy. The clearance rate of serum HCV RNA in group A (86.7%) was significantly higher than that in group B (13.3 %) at day 3 (p = 0.0006). No accumulation of IFN-β was shown in serum throughout the therapy. The ratio (day 3/day 1) of 2'5'-AS activity was significantly higher in group A. Multivariate analysis indicated twice-a-day IFN-β injection therapy led to significantly early clearance of circulating HCV. Twice-a-day IFN-β injection therapy could induce biologically enhanced antiviral activities and be an efficient induction therapy for eradication of HCV.

UR - http://www.scopus.com/inward/record.url?scp=0033800280&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033800280&partnerID=8YFLogxK

U2 - 10.1089/10799900050151102

DO - 10.1089/10799900050151102

M3 - Article

VL - 20

SP - 831

EP - 836

JO - Journal of Interferon and Cytokine Research

JF - Journal of Interferon and Cytokine Research

SN - 1079-9907

IS - 9

ER -